Vascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy
Abstract
Angiogenesis is a process of development and of growth of new capillary blood vessels from pre-existing vessels. When pathological, it contributes to the development of numerous types of tumors, and the formation of metastases. In order to grow, carcinoma need new blood vessels to form so that they can feed themselves. Therefore, nowadays the concept according to which the development of cancer is angiogenesis dependent is generally recognized. This concept makes the control of tumoral angiogenesis one of the promising therapeutic ways in cancerology. The transition from the latent phase to the invasive and metastatic phase of a cancer is linked to what is called the angiogenic switch. It implies complex cellular and molecular interactions between cancerous cells, endothelial cells and the components of the extra-cellular matrix and namely the existence of specific proteins secreted by the tumoral cells able to stimulate the proliferation of capillary endothelial cells. Among them, VEGF, Vascular Endothelial Growth Factor was found in several types of tumors. It has shown a tumoral angiogenic activity in vitro and in vivo, and thus is a privileged target for the control of angiogenesis in an anti-tumoral goal. The role of VEGF in tumoral angiogenesis has been extensively studied. It has been proved to undergo as well autocrine as paracrine stimulation of tumoral angiogenesis. During the last few years, several members of the VEGF family have been described namely the VEGF-A, B, C, D, E and placenta growth factor (PlGF) among which VEGF-A (121 aminoacids) plays a role of prime importance in angiogenesis. VEGF is a 45 kDA glycoprotein, homodimeric, basic, and able to bind heparin. The three-dimensional structure of VEGF has been recently determined, by X-rays diffraction, and NMR spectroscopy. The different forms of the VEGF bind to receptors that exhibit a tyrosine-kinase activity (RTK). The specific action of the VEGF on the endothelial cells is mainly regulated by two types of RTK of the VEGF family, VEGFR1, or Flt-1, and VEGFR2, or KDR/Flk-1. Mutagenesis studies have shown that only a small number of VEGF residues are important and essential for the binding with RTK. Data described to date from the studies of VEGF/RTK interactions agree to the hypothesis that KDR receptor is the main human receptor responsible for the VEGF activity in both physiological and pathological vascular development, and VEGF-KDR signalling pathway has been validated as a priority target for the development of anti- and pro- angiogenic agents. Therefore angiogenesis mediated by VEGF constitutes a new target for anti-cancer therapy which has explored through different ways of intervention aiming at the blocking of the tumoral angiogenesis. The main ones are: -Struggle against the stroma degradation and invasion by the neo-vessels -Inhibition of activated endothelial cells. -Inhibition of angiogenic factors production and of their receptors. -Inhibition of the VEGF signal pathway, by peptides blocking the bond between VEGF and its receptors through the inhibition of intracellular transduction of VEGF signal. In conclusion, this bibliographic study allows to situate works of medicinal chemistry in the context of present knowledge concerning the vascular endothelial growth factor (VEGF) and its role in angiogenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antineoplastic drugs that target the VEGF pathway have emerged as inducers of hypertension in patients being treated for malignancies.
“In patients being treated for malignancies, antineoplastic drugs that target the VEGF (vascular endothelial growth factor) pathway have emerged as inducers of hypertension.225–227”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [227]
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 485 · see citing works
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 452 · see citing works
“Both VEGF and FGF-2 are key regulators of angiogenesis and are implicated in enhancing tumor progression (reviewed in Boudreau and Myers, 2003; Detillieux et al., 2003; Ferrara et al., 2003; Shinkaruk et al., 2003; Streit and Detmar 2003).”
BackgroundBremnes, R. M., Camps, C., & Sirera, R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.09.005 · Cited by 330 · see citing works
Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids
Auti, P. S., George, G., & Paul, A. T. (2020) · RSC Advances · doi:10.1039/d0ra06642g · Cited by 328 · see citing works
Anticancer and Cancer Chemopreventive Potential of Grape Seed Extract and Other Grape-Based Products
Kaur, M., Agarwal, C., & Agarwal, R. (2009) · Journal of Nutrition · doi:10.3945/jn.109.106864 · Cited by 249 · see citing works
Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment
Welle, M. M., Bley, C. R., Howard, J., & Rüfenacht, S. (2008) · Veterinary Dermatology · doi:10.1111/j.1365-3164.2008.00694.x · Cited by 246 · see citing works
Wang, N., Wang, Z., Mo, S., Loo, T. Y., Wang, D.-M., Luo, H., Yang, D., Chen, Y., Shen, J., & Chen, J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1977-9 · Cited by 210 · see citing works
“Besides, the downstream structure from the fourth to seventh immunoglobulin-like domains in VEGFR-2 plays a major role in dimerization and activation [39].”
BackgroundMethylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation
Singleton, P. A., Lingen, M. W., Fekete, M. J., Garcia, J. G. N., & Moss, J. (2006) · Microvascular Research · doi:10.1016/j.mvr.2006.04.004 · Cited by 176 · see citing works
Siddique, A. N., Nunna, S., Rajavelu, A., Zhang, Y., Jurkowska, R. Z., Reinhardt, R., Rots, M. G., Ragozin, S., Jurkowski, T. P., & Jeltsch, A. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.11.038 · Cited by 172 · see citing works
MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer
Lü, Y., Qin, T., Li, J. S., Wang, L., Zhang, Q., Jiang, Z., & Mao, J. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.30 · Cited by 170 · see citing works
Adjuvant Therapy in Gastric Cancer
Lim, L., Michael, M., Mann, G. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.593 · Cited by 143 · see citing works
Marine polysaccharides: therapeutic efficacy and biomedical applications
Lee, Y., Kim, H., Seo, C., Park, T., Lee, K. B., Yoo, S., Hong, S., Kim, J. T., & Lee, J. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0958-2 · Cited by 142 · see citing works
“VEGF is able to regulate vessel permeability, thus promoting tumor metastasis (Shinkaruk et al. 2003).”
BackgroundARK5 Is a Tumor Invasion-Associated Factor Downstream of Akt Signaling
Suzuki, A., Lu, J., Kusakai, G.-I., Kishimoto, A., Ogura, T., & Esumi, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3526-3535.2004 · Cited by 134 · see citing works
Nanoparticles of Copper Stimulate Angiogenesis at Systemic and Molecular Level
Mroczek-Sosnowska, N., Sawosz, E., Vadalasetty, K. P., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16034838 · Cited by 123 · see citing works
“VEGF is recognized as the key regulator of angiogenesis, and is more efficient than FGF2 in the stimulation of differentiation of endothelial cells [5].”
Zilberberg, L., Shinkaruk, S., Lequin, O., Rousseau, B., Hagedorn, M., Costa, F., Caronzolo, D., Balke, M., Canron, X., Convert, O., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304435200 · Cited by 113 · see citing works
Self-citationHuang, T., Chiu, Y., Chan, Y.-L., Chiu, Y.-H., Wang, H., Huang, K., Li, T., Hsu, K., & Wu, C. (2015) · Marine Drugs · doi:10.3390/md13041882 · Cited by 105 · see citing works
Lin, Z., Chuang, Y.-H., & Chuang, W. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.02.001 · Cited by 100 · see citing works
Patel, N. S., Mathura, V. S., Bachmeier, C. J., Beaulieu‐Abdelahad, D., Laporte, V., Weeks, O. I., MULLAN, M. J., & Paris, D. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06426.x · Cited by 99 · see citing works
“For this reason, inhibitors of the VEGF pathway represent attractive targets for anti-tumoral therapies (Zhu and Witte 1999; Shinkaruk et al. 2003).”
BackgroundMoyamoya disease: a review of histopathology, biochemistry, and genetics
Weinberg, D. G., Arnaout, O. M., Rahme, R. J., Aoun, S. G., Batjer, H. H., & Bendok, B. R. (2011) · Neurosurgical FOCUS · doi:10.3171/2011.3.focus1151 · Cited by 99 · see citing works
“29 It plays a central role in pathological vasculogenesis and vascular permeability in intracranial lesions.”
BackgroundDocosahexaenoic acid stimulates tube formation in first trimester trophoblast cells, HTR8/SVneo
Johnsen, G. M., Basak, S., Weedon-Fekjær, M. S., Staff, A. C., & Duttaroy, A. K. (2011) · Placenta · doi:10.1016/j.placenta.2011.06.009 · Cited by 95 · see citing works
“VEGF strongly induces angiogenesis and increases permeability of blood vessels [5].”
BackgroundEndothelial Progenitor Cells in Tumor Angiogenesis: Another Brick in the Wall
Marçola, M., & Rodrigues, C. E. (2015) · Stem Cells International · doi:10.1155/2015/832649 · Cited by 92 · see citing works
“In addition, because of the high VEGFR-1 binding affinity without activation of downstream signaling, VEGFR-1 is considered to be a trap receptor,makingVEGF-A less available to VEGFR-2 binding [54].”
BackgroundInfluentialMelatonin and cancer: From the promotion of genomic stability to use in cancer treatment
Farhood, B., Goradel, N. H., Mortezaee, K., Khanlarkhani, N., Najafi, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27391 · Cited by 91 · see citing works
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis
Baka, S., Clamp, A. R., & Jayson, G. C. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.867 · Cited by 89 · see citing works
“Data described, so far, from the studies of VEGF/RTK interactions support the hypothesis that the VEGFR-2 receptor is the main human receptor responsible for VEGF activity in both physiological and pathological vascular development and VEGF-VEGFR-2 signalling pathway has been validated as a priority target for the dev…”
BackgroundCommon Secondary Causes of Resistant Hypertension and Rational for Treatment
Faselis, C. J., Doumas, M. N., & Papademetriou, V. (2011) · International Journal of Hypertension · doi:10.4061/2011/236239 · Cited by 87 · see citing works
“A monoclonal antibody (bevacizumab) binding to the VEGF-A isoform, as well as small molecules inhibiting the intracellular tyrosine kinase domains of all three VEGF receptors, is used or is under clinical testing for the treatment of various malignancies [55–57].”
MethodSo, J., Wang, F., Navari, J., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.03.004 · Cited by 84 · see citing works
Emerging therapeutic targets in schwannomas and other merlin-deficient tumors
Ammoun, S., & Hanemann, C. O. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.82 · Cited by 83 · see citing works
Peng, F.-W., Ji, X., Wu, T.-T., Xue, J., Ren, Z., Liu, D., Wang, X., Chen, X.-H., Zhang, J., Xu, Y., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.033 · Cited by 78 · see citing works
HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation
Spina, A., Pasquale, V. D., Cerulo, G., Cocchiaro, P., Morte, R. D., Avallone, L., & Pavone, L. M. (2015) · Biomedicines · doi:10.3390/biomedicines3010071 · Cited by 75 · see citing works
“In conclusion, a consistent picture of how the stromal cells (CAFs and inflammatory cells, such as TAMs, MDSCs, and mast cells) can promote tumor malignant progression has been extensively depicted.”
BackgroundInfluentialHarmange, J.-C., Weiss, M. M., Germain, J., Polverino, A. J., Borg, G., BREADY, J. V., Chen, D., Choquette, D. M., Coxon, A., DeMelfi, T., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701097z · Cited by 74 · see citing works
Kumar, P., Benedict, R., Urzua, F., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700272 · Cited by 73 · see citing works
“9 Numerous efforts have been directed at developing strategies to use VEGF as a potential therapeutic target”
BackgroundVascular endothelial growth factor: An important molecular target of curcumin
Saberi‐Karimian, M., Katsiki, N., Caraglia, M., Boccellino, M., Majeed, M. A., & Sahebkar, A. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1366892 · Cited by 74 · see citing works
Role of HIF Signaling on Tumorigenesis in Response to Chronic Low-Dose Arsenic Administration
Kamat, C. D., Green, D. E., Curilla, S., Warnke, L. A., Hamilton, J. W., Stürup, S., Clark, C., & Ihnat, M. A. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi190 · Cited by 72 · see citing works
“Vascular endothelial growth factor (VEGF) has been shown to be a critical factor in tumor-related angiogenesis and is a primary therapeutic target for the treatment of cancer through angiogenesis inhibition (reviewed in Shinkaruk et al., 2003).”
BackgroundMolecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
Scartozzi, M., Galizia, G., Freddari, F., et al. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.01.001 · Cited by 71 · see citing works
Zakraoui, O., Marcinkiewicz, C., Aloui, Z., Othman, H., Grépin, R., Haoues, M., Essafi, M., Srairi‐Abid, N., Gasmi, A., Karoui, H., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22470 · Cited by 68 · see citing works
“ing target for anti-cancer therapy [81] and agents targeting the VEGF pathway increased the efficacy of chemotherapy resulting in the extension of survival [80].”
BackgroundEl-Mousawi, M., Tchistiakova, L., Yurchenko, L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308681200 · Cited by 66 · see citing works
VEGF Trap Abolishes Shear Stress‐ and Overload‐Dependent Angiogenesis in Skeletal Muscle
Williams, J. L., Cartland, D., Rudge, J. S., & Egginton, S. (2006) · Microcirculation · doi:10.1080/10739680600785717 · Cited by 64 · see citing works
Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome
Chen, S.-T., Pan, T., Juan, H., Chen, T., Lin, Y.-S., & Huang, C. (2008) · Journal of Proteome Research · doi:10.1021/pr700745n · Cited by 64 · see citing works
Rebuzzi, L., Willmann, M., Sonneck, K., et al. (2006) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2006.11.009 · Cited by 64 · see citing works
Zambonin, L., Caliceti, C., Sega, F. V. D., Fiorentini, D., Hrelia, S., Landi, L., & Prata, C. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/839298 · Cited by 62 · see citing works
“tumour growth and proliferation [56–61].”
Ai, K., Lu, L.-Y., Huang, X., et al. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1931 · Cited by 63 · see citing works
VEGF kinase inhibitors: how do they cause hypertension?
Bhargava, P. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90502.2008 · Cited by 63 · see citing works
Glucose metabolic phenotype of pancreatic cancer
Chan, A. K. C., Bruce, J. I. E., & Siriwardena, A. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i12.3471 · Cited by 60 · see citing works
Stefanini, M. O., Wu, F. T. H., Gabhann, F. M., et al. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000622 · Cited by 61 · see citing works
“Human VEGF consists of at least seven isoforms: VEGF121, VEGF145, VEGF148, VEGF165, VEGF183, VEGF189, and VEGF206 [4,5].”
BackgroundInfluentialLiao, X., Tao, L.-T., Liu, J., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0495-6 · Cited by 61 · see citing works
“Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumor vascularisation and tumour growth [23, 24].”
BackgroundThe roles and role-players in thyroid cancer angiogenesis
Rajabi, S., Dehghan, M. H., Dastmalchi, R., Mashayekhi, F. J., Salami, S., & Hedayati, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0537 · Cited by 61 · see citing works
“or organ depends upon the number of vessels already present during the initiation of the fast development of the organ or the tumor [31].”
BackgroundChetty, C., Lakka, S. S., Bhoopathi, P., Kunigal, S., Geiss, R., & Rao, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6612 · Cited by 60 · see citing works
“VEGFR2 is the main human receptor responsible for both physiologic and pathologic vascular development, and the VEGF-VEGFR2 signaling pathway has become an important target for the development of antiangiogenic agents (36).”
BackgroundIshii, H., Yazawa, T., Sato, H., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.02.021 · Cited by 60 · see citing works
“Moreover, some studies have focused on the suppression of tumor growth by blocking VEGF signaling using monoclonal antibody, antisense expression vectors, or VEGFR inhibitors [14,29—37].”
BackgroundRole of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy
Becker, J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i21.3297 · Cited by 59 · see citing works
Pignot, G., Bièche, I., Vacher, S., et al. (2008) · European Urology · doi:10.1016/j.eururo.2008.05.027 · Cited by 57 · see citing works
Zhukova, N., Rajagopal, R., Lam, A., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1799 · Cited by 56 · see citing works
Immobilization of glycoproteins, such as VEGF, on biodegradable substrates
Sharon, J. L., & Puleo, D. A. (2008) · Acta Biomaterialia · doi:10.1016/j.actbio.2008.02.017 · Cited by 52 · see citing works
“VEGF is a key regulator of angiogenesis [11].”
Chellappan, D. K., Leng, K. H., Jia, L. J., Aziz, N. A. B. A., Hoong, W. C., Qian, Y. C., Ling, F. Y., Wei, G. S., Ying, T., Chellian, J., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.061 · Cited by 53 · see citing works
Shariat, S. F. (2008) · European Urology · doi:10.1016/j.eururo.2008.05.028 · Cited by 49 · see citing works
Farombi, E. O., Ajayi, B. O., & Adedara, I. A. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111483 · Cited by 46 · see citing works
Chwalibóg, A., Wierzbicki, M., Sawosz, E., Grodzik, M., Hotowy, A., Prasek, M., Jaworski, S., & Sawosz, F. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s49745 · Cited by 43 · see citing works
Terfezia boudieri: A Desert Truffle With Anticancer and Immunomodulatory Activities
Obaydi, M. F. A., Hamed, W. M. A. A. S., Kury, L. T. A., et al. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00038 · Cited by 43 · see citing works
“This protein is an important target in cancer treatment to inhibit cancer cells proliferation by the prevention of blood vessels formation (33).”
BackgroundNovel metal nanomaterials to promote angiogenesis in tissue regeneration
Yoshida, Y. G., Su, Y., Xu, H., & Yang, J. Y. (2023) · Engineered Regeneration · doi:10.1016/j.engreg.2023.03.008 · Cited by 41 · see citing works
Control of integrin genes expression in the eye
Vigneault, F., Zaniolo, K., Gaudreault, M., Gingras, M.-E., & Guérin, S. L. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.10.004 · Cited by 41 · see citing works
Gomez‐Rivera, F., Santillan-Gomez, A. A., Younes, M. N., Kim, S. W., Fooshee, D. R., Zhao, M., Jasser, S. A., & Myers, J. N. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2636 · Cited by 40 · see citing works
Gangjee, A., Kurup, S., Ihnat, M. A., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.052 · Cited by 40 · see citing works
Rahman, M., Mamun, A. A., Karim, M. R., Islam, K., Amin, H. A., Hossain, S., Hossain, M. I., Saud, Z. A., Noman, A. S. M., Miyataka, H., et al. (2014) · Chemosphere · doi:10.1016/j.chemosphere.2014.08.003 · Cited by 40 · see citing works
Cai, S., Yang, Q., Hou, M., Han, Q., Zhang, H., Wang, J., Chen, Q., Bo, Q., Ru, Y., Yang, W., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487029 · Cited by 39 · see citing works
Fava, G., DeMorrow, S., Gaudio, E., Franchitto, A., Onori, P., Carpino, G., Glaser, S. S., Francis, H., Coufal, M., Marucci, L., et al. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.01997.x · Cited by 38 · see citing works
“We propose that the inhibition of cholangiocarcinoma growth by ET-1 is also due to a decreased synthesis or release of VEGF-A and VEGF-C, which (in addition to regulating cholangiocyte functions) (25, 26) are potent inductors of vascularization, development and growth of several cancers (5, 55), such as cholangiocarci…”
BackgroundProkineticins and their G protein-coupled receptors in health and disease
Zhao, Y., Wu, J., Wang, X., Jia, H., Chen, D., & Li, J. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.09.006 · Cited by 40 · see citing works
Liu, T., Mu, L.-Q., Dai, W., et al. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s101918 · Cited by 37 · see citing works
“associated with the development of various types of tumors.(47) VEGF is capable of binding to receptor tyrosine kinase (RTK), so it can activate the RTK on the endothelial cell surface, thereby promoting the proliferation of endothelial cells and participating in angiogenesis.”
Imidazo[1,2-a]pyrazine diaryl ureas: Inhibitors of the receptor tyrosine kinase EphB4
Mitchell, S. A., Danca, M. D., Blomgren, P. A., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.037 · Cited by 37 · see citing works
Hsieh, M., Lin, Z., & Chuang, W. (2011) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2011.03.008 · Cited by 35 · see citing works
“The VEGF family has at least seven members, and VEGF-A is a key player in angiogenesis [2,3].”
BackgroundNoninvasive characterization of the healthy human manubrium using diffuse optical spectroscopies
Farzam, P., Lindner, C., Weigel, U. M., et al. (2014) · Physiological Measurement · doi:10.1088/0967-3334/35/7/1469 · Cited by 35 · see citing works
Young, H. S., Weidmann, A. K., Crawshaw, A. A., & Byrne, E. (2013) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s35312 · Cited by 35 · see citing works
“31 Of these, VEGF-A (initially known as vascular permeability factor) was the first to be discovered and exists as four isoforms (VEGF-A121, VEGF-A165, VEGF-A189, VEGF-A206) 32 generated by variable splicing of the VEGF-A gene.”
Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression
Chen, M., Lin, M., & Wang, X. (2017) · Oncology Reports · doi:10.3892/or.2017.6110 · Cited by 35 · see citing works
Patsouras, D., Papaxoinis, K., Kostakis, A. I., et al. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3259 · Cited by 34 · see citing works
The potential role of nintedanib in treating colorectal cancer
Rossi, A., Latiano, T. P., Parente, P., Chiarazzo, C., Limosani, F., Maggio, G. D., & Maiello, E. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1346086 · Cited by 32 · see citing works
“VEGFR-3 is activated by VEGF-C and VEGF-D and has been found to be primarily associated with lymphangiogenesis [14,15].”
BackgroundKaza, E., Ablasser, K., Poutias, D., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq321 · Cited by 32 · see citing works
Borden, K. L. B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.06.005 · Cited by 32 · see citing works
“Note that increased VEGF levels correlate with increased metastasis [112,113].”
BackgroundHou, Z., Zhu, K., Yang, X., Chen, P., Zhang, W., Cui, Y., Zhu, X., Song, T., Li, Q., Li, H., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2990 · Cited by 31 · see citing works
“Vascular endothelial growth factor (VEGF) signaling is considered to be the main pathway responsible for angiogenesis (8-11), with VEGFR2 being a critical mediator of VEGF-induced angiogenic signaling (12).”
BackgroundMetastasis models: the green fluorescent revolution?
Paris, S. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh219 · Cited by 31 · see citing works
Indirubin derivative E804 inhibits angiogenesis
Shin, E.-K., & Kim, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-164 · Cited by 30 · see citing works
“Accordingly, the VEGF signaling pathway has become an important target for anti-cancer treatment and many approaches have been developed to inhibit this pathway [8,9].”
BackgroundLin, Z., & Chuang, W. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.08.012 · Cited by 30 · see citing works
“Besides PGK1 gene, HCC38/KMUH cancer cells only upregulated APLN, LOXL2, and VEGFA genes and HCC24/KMUH cancer cells only up-regulated FGF2 gene in F26/KMUH CAFs.”
BackgroundInfluentialGautier, B., Gonçalves, V., Diana, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002167 · Cited by 30 · see citing works
Zhao, C., Xu, Y., Wu, P., et al. (2023) · Odontology · doi:10.1007/s10266-023-00793-1 · Cited by 29 · see citing works
“VEGF has a very high affinity and can directly or indirectly promote angiogenesis [26].”
BackgroundAziz, Y. M. A., Said, M. M., Shihawy, H. A. E., et al. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.03.004 · Cited by 29 · see citing works
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation
Heffelfinger, S. C., Yan, M., Gear, R. B., Schneider, J., LaDow, K., & Warshawsky, D. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700128 · Cited by 29 · see citing works
Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis
Malecic, N., & Young, H. S. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1153064 · Cited by 28 · see citing works
“[22] VEGF specifically stimulates mitosis in endothelial cells, increases vascular permeability, and contributes to chemotaxis and activation of monocytes.[19,21,23] VEGF ligands selectively bind to VEGFRs, which are tyrosine kinases (TK)s.”
BackgroundLandry, J. P., Fei, Y., Zhu, X. D., Ke, Y., Yu, G., & Lee, P. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2012.485 · Cited by 27 · see citing works
“We used plated sets from NCI/DTP with a total of 7,961 compounds: (1) a Challenge set with 57 compounds (10 mM); (2) a Natural Products set with 235 compounds (10 mM); (3) a Structural Diversity set with 1,990 compounds (10 mM); (4) a Mechanistic Diversity set with 879 compounds (1 mM); and (5) an Open set with 4,800…”
MethodLi, Y., Wang, W., Zhang, Y., et al. (2019) · Biomaterials Science · doi:10.1039/c8bm01337c · Cited by 27 · see citing works
Akkad, T., Tzankov, A., Pelzer, A. E., et al. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01490.x · Cited by 26 · see citing works
Han, Y., Xiao, Y., Yu, L., et al. (2023) · Journal of Cancer · doi:10.7150/jca.80456 · Cited by 24 · see citing works
“Angiogenesis, the process of forming new blood vessels and blood supply structures, is one of the important mechanisms of tumor growth and metastasis [73].”
BackgroundAli, F., Khalid, M., Masmoudi, A., et al. (2024) · Journal of Computational Science · doi:10.1016/j.jocs.2024.102448 · Cited by 23 · see citing works
Young, A. M. H., Karri, S. K., Ogilvy, C. S., et al. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00105 · Cited by 23 · see citing works
“VASCULAR ENDOTHELIAL GROWTH FACTOR Vascular endothelial growth factor is a 45-kD homodimeric, basic glycoprotein that requires association with heparin in order to function (27).”
BackgroundHamden, K. E., Ford, P. W., Whitman, A. G., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13381-13390.2004 · Cited by 23 · see citing works
“by on January 30, 2010 jvi.asm.org Downloaded from other tumor conditions (42, 52 ).”
BackgroundPerspectives in PML: a unifying framework for PML function
Borden, K. L. B. (2009) · Frontiers in bioscience · doi:10.2741/3258 · Cited by 23 · see citing works
“Increased VEGF levels correlate with increased metastatic disease (91, 92).”
BackgroundZhuo, H., Lyu, Z., Su, J., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr5006229 · Cited by 21 · see citing works
Identification of novel cytokine biomarkers of hexanal exposure associated with pulmonary toxicity
Cho, Y., Song, M., Kim, T. S., & Ryu, J. (2017) · Environmental Pollution · doi:10.1016/j.envpol.2017.06.041 · Cited by 21 · see citing works
Giusti, G., Lee, J., Kremer, T. L., Friedrich, P. F., Bishop, A. T., & Shin, A. Y. (2014) · Microsurgery · doi:10.1002/micr.22371 · Cited by 21 · see citing works
Martinotti, S., Ranzato, E., Parodi, M., et al. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.10.025 · Cited by 20 · see citing works
Pompeng, P., Sommit, D., Sriubolmas, N., et al. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.03.019 · Cited by 20 · see citing works
von Rahden, B. H. A., Brücher, B. L. D. M., Langner, C., et al. (2006) · British journal of surgery · doi:10.1002/bjs.5426 · Cited by 20 · see citing works
Tang, Y., Yu, F., Zhang, G., et al. (2017) · Molecules · doi:10.3390/molecules22071123 · Cited by 19 · see citing works
“VEGF promotes vascular endothelial growth and mediates vascular permeability, thereby promoting tumor progression and metastatic diffusion [32].”
BackgroundYang, P., Xiong, J., Zuo, L., et al. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9291 · Cited by 19 · see citing works
“VEGF is a member of the platelet-derived growth factor family, which includes VEGFA, VEGFB, VEGFC, VEGFD and VEGFE (10).”
- Authors
- Shinkaruk, S., Bayle, M., Lain, G., & Deleris, G.
- Affiliations
- Inserm (FR)
- ORCID
- Shinkaruk, S.
- Venue
- Current Medicinal Chemistry-Anti-Cancer Agents
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-03-01
- Volume
- 3
- Issue
- 2
- Pages
- 95-117
- ISSN
- 1568-0118 (ISSN-L)
- OpenAlex
- W2070230256
- Cited by
- 219
- References
- 0
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 5 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 8 · 2018: 14 · 2017: 12 · 2016: 11 · 2015: 13 · 2014: 15 · 2013: 10 · 2012: 11
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Keywords
- vascular endothelial growth factor, angiogenesis, tumor angiogenesis, anti-angiogenic cancer therapy, VEGF receptors, VEGFR2, VEGFR1, VEGF-A, VEGF family, angiogenic switch, metastasis, autocrine and paracrine signaling, receptor tyrosine kinase, anti-VEGF therapy, VEGF inhibitors
- MeSH terms
- Animals, Endothelium, Vascular, Humans, Lymphokines, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Endothelial Growth Factors, Paracrine Communication, Angiogenesis Inhibitors, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
